Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain

被引:18
|
作者
Antonanzas F. [1 ]
Rive B. [2 ,5 ]
Badenas J.M. [3 ]
Gomez-Lus S. [3 ]
Guilhaume C. [4 ]
机构
[1] Department of Economics, Universidad de la Rioja
[2] Altipharm SA
[3] Lundbeck Spain SA, Barcelona
[4] International Department of Health Economics and Epidemiology, H. Lundbeck A/S
[5] Altipharm SA, 75001 Paris
关键词
Cost-effectiveness; Markov model; Memantine; Moderately severe to severe Alzheimer's disease; Spain;
D O I
10.1007/s10198-006-0355-0
中图分类号
学科分类号
摘要
Several clinical trials have demonstrated the efficacy and safety of the NMDA antagonist memantine in moderately severe to severe Alzheimer's disease (AD) patients. A 28-week pharmacoeconomic study conducted in the US also showed a reduction of total healthcare costs and informal care compared to placebo. Long-term implications of memantine treatment were modelled in the UK and Finland and revealed reductions in dependency, institutionalization and costs. However, these conclusions were not directly applicable to the Spanish setting where patients are mainly treated within the community. The objective of this study was to estimate the long-term implications in terms of costs and health benefits of memantine therapy compared to standard care using a Spanish adaptation of previous models over a 2-year time horizon. As in previous adaptations, Markov health states were defined as a combination of severity (mild-moderate, moderately severe, severe) and dependency plus death as the absorbing state. Spain-specific data (costs, mortality and epidemiological data) were obtained from local and recently published cohorts of AD patients. Data on the effectiveness of memantine were derived from a randomized double-blind placebo-controlled clinical trial of 252 moderately severe to severe AD patients. Effectiveness was measured as the time spent in a non-dependent health state. The evaluation was conducted over 2 years, while the efficacy of memantine was applied for 1 year only in order to ensure a conservative approach. The robustness of the model was tested by conducting stochastic analyses and various sensitivity analyses on the key assumptions. Patients receiving standard care were estimated to spend 6 months in a non-dependent state and to incur average total costs of €24,700 over 2 years. The memantine strategy was associated with an additional 2.5 months in a non-dependent state and a €700 cost reduction. Monte-Carlo simulations and sensitivity analyses supported these findings. Memantine appears to be cost-effective compared with standard care in moderately severe to severe AD patients in a Spanish setting. The prolonged independence provided by memantine treatment translated into cost reductions which offset drug costs and resulted in overall cost-savings. © 2006 Springer Medizin Verlag.
引用
收藏
页码:137 / 144
页数:7
相关论文
共 50 条
  • [41] Cost-effectiveness of a community-based cardiovascular disease prevention intervention in medically underserved rural areas
    Hua Wang
    Donald Kenkel
    Meredith L. Graham
    Lynn C. Paul
    Sara C. Folta
    Miriam E. Nelson
    David Strogatz
    Rebecca A. Seguin
    BMC Health Services Research, 19
  • [42] Cost-effectiveness of a community-based cardiovascular disease prevention intervention in medically underserved rural areas
    Wang, Hua
    Kenkel, Donald
    Graham, Meredith L.
    Paul, Lynn C.
    Folta, Sara C.
    Nelson, Miriam E.
    Strogatz, David
    Seguin, Rebecca A.
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [43] Effectiveness and Cost-Effectiveness of the Pharmacological Treatment of Alzheimer's Disease and Vascular Dementia
    Versijpt, Jan
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 : S19 - S25
  • [44] Cost-effectiveness of community-based childhood obesity prevention interventions in Australia
    Jaithri Ananthapavan
    Phuong K. Nguyen
    Steven J. Bowe
    Gary Sacks
    Ana Maria Mantilla Herrera
    Boyd Swinburn
    Vicki Brown
    Rohan Sweeney
    Anita Lal
    Claudia Strugnell
    Marj Moodie
    International Journal of Obesity, 2019, 43 : 1102 - 1112
  • [45] A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden
    Johansson, Pia
    Ostenson, Claes-Goran
    Hilding, Agneta
    Andersson, Camilla
    Rehnberg, Clas
    Tillgren, Per
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (03) : 350 - 358
  • [46] THE RELATIVE COST-EFFECTIVENESS OF HOME- AND COMMUNITY-BASED PROGRAMS IN FLORIDA
    Polivka, L.
    GERONTOLOGIST, 2009, 49 : 138 - 138
  • [47] Cost-effectiveness of community-based treatment of severe acute malnutrition in children
    Bachmann, Max Oscar
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (05) : 605 - 612
  • [48] Cost-effectiveness of community-based practitioner programmes in Ethiopia, Indonesia and Kenya
    McPake, Barbara
    Edoka, Ljeoma
    Witter, Sophie
    Kielmann, Karina
    Taegtmeyer, Miriam
    Dieleman, Marjolein
    Vaughan, Kelsey
    Gama, Elvis
    Kok, Maryse
    Datiko, Daniel
    Otiso, Lillian
    Ahmed, Rukhsana
    Squires, Neil
    Suraratdecha, Chutima
    Cometto, Giorgio
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2015, 93 (09) : 631 - 639
  • [49] COST-EFFECTIVENESS ANALYSIS OF COMMUNITY-BASED HIV CARE STRATEGIES IN MALI
    Cabout, E.
    Eymere, S.
    Dembele, B.
    Launois, R.
    VALUE IN HEALTH, 2022, 25 (01) : S99 - S99
  • [50] Community-Based Interventions for Newborns in Ethiopia (COMBINE): Cost-effectiveness analysis
    Mathewos, Bereket
    Owen, Helen
    Sitrin, Deborah
    Cousens, Simon
    Degefie, Tedbabe
    Wall, Stephen
    Bekele, Abeba
    Lawn, Joy E.
    Daviaud, Emmanuelle
    HEALTH POLICY AND PLANNING, 2017, 32 : 21 - 32